AYTU BIOPHARMA, INC Quarterly Liabilities and Equity in USD from Q3 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Aytu Biopharma, Inc quarterly Liabilities and Equity history and growth rate from Q3 2011 to Q2 2024.
  • Aytu Biopharma, Inc Liabilities and Equity for the quarter ending June 30, 2024 was $118M, a 13.5% decline year-over-year.
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $118M -$18.4M -13.5% Jun 30, 2024 10-K 2024-09-26
Q1 2024 $129M -$18.4M -12.5% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $131M -$10.2M -7.2% Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $133M -$17.1M -11.4% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $136M -$1.16M -0.84% Jun 30, 2023 10-K 2024-09-26
Q1 2023 $147M -$21.6M -12.8% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $141M -$82.4M -36.8% Dec 31, 2022 10-Q 2023-02-21
Q3 2022 $150M -$77.7M -34.1% Sep 30, 2022 10-Q/A 2023-02-21
Q2 2022 $138M -$128M -48.2% Jun 30, 2022 10-K 2023-10-12
Q1 2022 $169M -$103M -37.8% Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $224M +$57.1M +34.2% Dec 31, 2021 10-Q 2022-02-14
Q3 2021 $228M +$86.5M +61.2% Sep 30, 2021 10-Q 2021-11-15
Q2 2021 $266M +$112M +73.3% Jun 30, 2021 10-K 2022-09-27
Q1 2021 $272M +$113M +70.8% Mar 31, 2021 10-Q 2021-05-17
Q4 2020 $167M +$92.3M +124% Dec 31, 2020 10-Q 2021-02-11
Q3 2020 $141M +$110M +355% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 $153M +$119M +341% Jun 30, 2020 10-K 2021-09-28
Q1 2020 $159M +$121M +315% Mar 31, 2020 10-Q 2020-05-15
Q4 2019 $74.5M +$32.1M +75.7% Dec 31, 2019 10-Q 2020-02-14
Q3 2019 $31M +$13M +72.5% Sep 30, 2019 10-Q 2019-11-14
Q2 2019 $34.7M +$13.7M +64.9% Jun 30, 2019 10-K 2020-10-06
Q1 2019 $38.3M +$15M +64% Mar 31, 2019 10-Q 2019-05-14
Q4 2018 $42.4M +$23.5M +125% Dec 31, 2018 10-Q/A 2019-05-14
Q3 2018 $18M -$3.26M -15.4% Sep 30, 2018 10-Q 2018-11-07
Q2 2018 $21.1M +$6.06M +40.4% Jun 30, 2018 10-K 2019-09-26
Q1 2018 $23.4M +$7.46M +46.9% Mar 31, 2018 10-Q 2018-05-14
Q4 2017 $18.9M -$2.65M -12.3% Dec 31, 2017 10-Q 2018-02-08
Q3 2017 $21.2M +$1.05M +5.17% Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $15M -$9.34M -38.4% Jun 30, 2017 10-K 2018-09-06
Q1 2017 $15.9M -$6.07M -27.6% Mar 31, 2017 10-Q 2017-05-11
Q4 2016 $21.5M -$2.9M -11.9% Dec 31, 2016 10-Q 2017-02-09
Q3 2016 $20.2M -$1.16M -5.43% Sep 30, 2016 10-Q 2016-11-07
Q2 2016 $24.3M +$6.16M +33.9% Jun 30, 2016 10-K 2017-08-31
Q1 2016 $22M +$11.8M +116% Mar 31, 2016 10-Q 2016-05-11
Q4 2015 $24.4M +$24.4M Dec 31, 2015 10-Q 2016-02-11
Q3 2015 $21.4M +$21.4M Sep 30, 2015 10-Q 2015-11-06
Q2 2015 $18.2M +$6.17M +51.3% Jun 30, 2015 10-K 2016-09-01
Q1 2015 $10.2M +$10.2M Mar 31, 2015 10-Q 2015-05-19
Q4 2014 $11.2K* +$3.99K Nov 30, 2014 10-Q 2015-01-12
Q3 2014 $5.51K* -$4.16K Aug 31, 2014 10-Q 2015-04-15
Q2 2014 $12M +$12M Jun 30, 2014 10-K 2015-09-30
Q1 2014 $5.63K* -$7.48K Feb 28, 2014 10-Q 2014-04-11
Q4 2013 $7.16K* -$4.71K Nov 30, 2013 10-Q 2014-01-10
Q3 2013 $9.67K* -$2.98K Aug 31, 2013 10-K 2014-11-26
Q2 2013 $9.44K* -$4.59K May 31, 2013 10-Q 2013-06-28
Q1 2013 $13.1K* -$3.18K Feb 28, 2013 10-Q 2013-04-15
Q4 2012 $11.9K* -$18.8M Nov 30, 2012 10-Q 2013-01-14
Q3 2012 $12.6K* -$22.8M Aug 31, 2012 10-K 2014-11-26
Q2 2012 $14K* May 31, 2012 10-Q 2012-06-26
Q1 2012 $16.3K* Feb 29, 2012 10-Q 2012-04-12
Q4 2011 $18.8M Nov 30, 2011 10-Q 2011-12-23
Q3 2011 $22.8M Aug 31, 2011 10-K 2012-11-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.